Intramolecular nonbonded S···O interaction recognized in (acylimino)thiadiazoline derivatives as angiotensin II receptor antagonists and related compounds

Journal of the American Chemical Society

Volumn 120, Issue 13, 1998, Pages 3104-3110

  Nagao, Yoshimitsu ^a   Hirata, Terukage ^b   Goto, Satoru ^a   Sano, Shigeki ^a   Kakehi, Akikazu ^c   Iizuka, Kinji ^d   Shiro, Motoo ^e  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

^c SHINSHU UNIVERSITY   (Japan)

^d KISSEI PHARMACEUTICAL CO LTD   (Japan)

^e RIGAKU CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 THIADIAZOLINE DERIVATIVE; 2 [[5 ETHYL 3 [2' (1H TETRAZOL 5YL)BIPHENYL 4 YL]METHYL 1,3,4 THIADIAZOLIN 2 YLIDENE]AMINOCARBONYL] 1 CYCLOPENTENECARBOXYLIC ACID; 5 ETHYL 3 METHYL 2 [(TRIFLUOROACETYL)IMINO] 1,3,4 OXADIAZOLINE; 5 ETHYL 3 METHYL 2 [(TRIFLUOROACETYL)IMINO] 1,3,4 THIADIAZOLINE; 5 PROPYL 2 (TRIFLUOROACETAMIDO) 1,3,4 THIADIAZOLE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; HYPERTENSION; MOLECULAR INTERACTION; MOLECULAR STABILITY; X RAY CRYSTALLOGRAPHY;

EID: 0032495790     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja973109o     Document Type: Article

References (34)

1. (a) Kucsman, A.; Kapovits, I. Organic Sulfur Chemistry: Theoretical and Experimental Advances, Bernardi, F., Csizmadia, I. G., Mangini, A., Eds.; Elsevier Scientific Publishing Co.: Amsterdam, 1985; p 191-245.
2. (b) Ohkata, K.; Ohsugi, M.; Yamamoto, K.; Ohsawa, M.; Akiba, K. J. Am. Chem. Soc. 1996, 118, 6355-6369.
3. (a) L'abbe, G.; Meervelt, L. V.; Emmers, S.; Dehaen, W.; Toppet, S. J. Heterocycl. Chem. 1992, 29, 1765-1768.
4. (b) Cohen-Addad, C.; Lehmann, M. S.; Becker, P.; Párkányi, L.; Kálmán, A. J. Chem. Soc., Perkin Trans. 2 1984, 191-196.
5. (c) Cohen-Addad, C.; Savariault, J.-M.; Lehmann, M. S. Acta Crystallogr. 1981, B37, 1703-1706.
6. (d) Kálmán, A.; Párkányi, L. Acta Crystallogr. 1980, B36, 2372-2378.
7. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. J. Med. Chem. 1996, 39, 625-656.
8. (a) Hirata, T.; Nomiyama, J.; Sakae, N.; Nishimura, K.; Yokomoto, M.; Inoue, S.; Tamura, K.; Okuhira, M.; Amano, H.; Nagao, Y. Bioorg. Med. Chem. Lett. 1996, 6, 1469-1474.
9. (b) Hirata, T.; Goto, S.; Tamura, K.; Okuhira, M.; Nagao, Y. Bioorg. Med. Chem. Lett. 1997, 7, 385-388.
10. (c) Tamura, K.; Okuhira, M.; Amano, H.; Inokuma, K.; Hirata, T.; Mikoshiba, I.; Hashimoto, K. J. Cardiovasc. Pharmacol. 1997, 30, 607-615.
11. (a) Franchetti, P.; Cappellacci, L.; Grifantini, M.; Barzi, A.; Nocentini, G.; Yang, H.; O'Connor, A.; Jayaram, H. N.; Carrell, C.; Goldstein, B. M. J. Med. Chem. 1995, 38, 3829-3837.
12. (b) Goldstein, B. M.; Li, H.; Hallows, W. H.; Langes, D. A.; Franchetti, P.; Cappellacci, L.; Grifantini, M. J. Med. Chem. 1994, 37, 1684-1688.
13. (c) Li, H.; Hallows, W. H.; Punzi, J. S.; Marquez, V. E.; Carrell, H. L.; Pankiewicz, K. W.; Watanabe, K. A.; Goldstein, B. M. Biochemistry 1994, 33, 23-32.
14. (d) Goldstein, B. M.; Takusagawa, F.; Berman, H. M.; Srivastava, P. C.; Robins, R. K. J. Am. Chem. Soc. 1983, 105, 7416-7422.
15. Compound 3 shows the strongest angiotensin II antagonistic activity in vitro and in vivo among a series of (acylimino)thiadiazoline derivatives. This compound referred to KRH-594 is now under clinical trial as a antihypertensive agent in Japan.
16. Synthesis and detailed biological activity of (acylimino)oxadiazoline derivative 4 will be reported elsewhere.
17. Hirata, T.; Shiro, M.; Nagao. Y. Heterocycles 1997, 44, 133-138.
18. Binkley, J. S.; Pople, J. A.; Hehre, W. J. J. Am. Chem. Soc. 1980, 102, 939-947.
19. The ab initio calculations were performed using Gaussian 92 programs: Frisch, M. J.; Trucks, G. W.; Head-Gordon, M.; Gill, P. M. W.; Wong, M. W.; Foresman, J. B.; Johnson, B. G.; Schlegel, H. B.; Robb, M. A.; Replogle, E. S.; Gomperts, R.; Andres, J. L.; Raghavachari, K.; Binkly, J. S.; Gonzales, C.; Martin, R. L.; Fox, D. J.; Defrees, D. J.; Baker, J.; Steward, J. J. P.; Pople, J. A., Gaussian 92; GAUSSIAN, Inc.: Pittsburgh, 1993.
20. 3CO-N=) arrangements, respectively.
21. Hariharan, P. C.; Pople, J. A. Theor. Chim. Acta 1973, 28, 213-222.
22. Krishnan, R.; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650-654.
23. (a) Becker, P.; Cohen-Addad, C.; Delly, B.; Hirshfeld, F. L.; Lehmann, M. S. A Theoretical Study of Short S-O "Non-bonded" Interaction. In Applied Quantum Chemistry; Smith, V. H., Jr., Schaefer, H. F., III, Morokuma, K., Eds.; D. Reidel: Boston, 1986; pp 361-373.
24. (b) Barbieri, G.; Benassi, R.; Taddei, F. J. Mol. Struct. 1989, 184, 269-276.
25. Ángyán, J. G.; Poirier, R. A.; Kucsman, Á.; Csizmadia, I. G. J. Am. Chem. Soc. 1987, 109, 2237-2245.
26. Burling, F. T.; Goldstein, B. M. J. Am. Chem. Soc. 1992, 114, 2313-2320.
27. (a) Abtstracts of the 5th Annual Meeting of Division of Medicinal Chemistry in Japan (Toyama), 1996.
28. (b) Tanaka, R.; Oyama, Y.; Imajo, S.; Matsuki, S.; Ishiguro, M. Bioorg. Med. Chem. 1997, 5, 1389-1399.
29. Nagao, Y.; Nagase, Y.; Kumagai, T.; Matsunaga, H.; Abe, T.; Shimada, O.; Hayashi, T.; Inoue, Y. J. Org. Chem. 1992, 57, 4243-4249.
30. Katritzky, A. R.; and Rees, C. W. Comprehensive Heterocyclic Chemistry; Pergamon Press Inc.: New York, 1984; Vol 6.
31. (a) MITHRIL84: Gilmore, C. J. J. Appl. Crystallogr. 1984, 17, 42-46.
32. (b) SHELXS86. Sheldrick, G. M., Program for the Solution of Crystal Structures, University of Gottingen, Germany, 1985.
33. (c) SIR92: Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, M.; Giacovazzo, C.; Guagliardi, A.; Polidori, G. J. Appl. Crystallogr. 1994, 27, 435.
34. teXsan: Crystal Structure Analysis Package, Molecular Structure Corporation, 1996.